All
Meta-analysis on DME treatments updated to include treatment regimen
FISH in focus for fast eye infection diagnosis
Despite cost, advantages include sensitivity, improved outcomes
US, international physicians mostly in agreement over treatment practices
This year’s ASRS PAT survey show subtle regional differences
Global trends show similar patterns worldwide
The ASRS Global Trends Survey finds differences in some treatment preferences
ASRS 2019 Street Team: John T. Thompson, MD
ICYMI: ASRS-developed program aims to support physicians with confidential comparisons
ASRS 2019 Street Team: Netan Choudhry, MD, FRCSC, DABO
Defining medicine and terms used can help move science forward
ASRS 2019 Street Team: Justis P. Ehlers, MD
Researchers seeking fluid features, retinal integrity measures to test next step in image analysis and image interrogation in clinical trials.
ASRS 2019 Street Team: David S. Boyer, MD
David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.
Intravenous prostaglandin E1 infusion for acute central retinal artery occlusion
The study finds that treatment resulted in a significant visual improvement.
ARVO heads north to Vancouver for 2019 annual meeting
‘From the Bench to Bedside and Back’ is focal point for this year’s conference
Ongoing study evaluates sirolimus as therapeutic option for uveitis
Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action
Read-through, gene therapies for LCA showing promise
Group of researchers aim to validate both approaches in proof-of-concept study
Biologics may offer systemic therapy option for uveitis
One biologic response modifier has indication for uveitis; several in development to gain FDA approval
Celebrating retina research, future generation of EyeMDs
Fifteen fellows, residents showed just why research in retina is on the cutting edge
Decreasing burden of nAMD therapy
Investigators optimistic about sustained-release ranibizumab delivery based on phase II LADDER study
Novel treatments in pipeline for diabetic eye disease
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.
Data promising in uveitic macular edema pivotal trial
Novel local corticosteroid therapy shows positive efficacy signals, favorable safety profile says Rahul Khurana, MD.
Laser therapy may offer fast-acting option for CSR resolution
Patients tolerate therapy well; high safety profile allows re-treatment as necessary
Commercial cell therapy clinics yield little evidence
Research finds limited publications and dearth of information about side effects
The subthreshold laser’s role in retinal vascular disease
Combination therapy benefits from laser in the mix for DME, other conditions
A study shows Alzheimer’s disease biomarkers in the vitreous
Understanding the variances of hypersonic vitrector settings
Sunir J. Garg, MD, discusses hypersonic vitrector settings in surgery in the exhibition hall at ASRS 2018 in Vancouver.
OCTA may be harbinger of anti-VEGF efficacy
When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.
Anti-VEGFs can improve DRSS in majority of patients
Progression to surgery for ERMs with good vision
Achromatopsia: Understanding the rare inherited retinal disease
CEO of Aerie Pharmaceuticals provides a brief company overview at OIS meeting
Incorporating office-based electrophysiology into everyday practice
Parafoveal retinal vessel density assessment by OCTA in healthy eyes
Study aims to identify methodology for least amount of variation, greatest test-retest reliability
Brolucizumab: Next-generation of anti-VEGF therapy?